Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOCATE: 18F-fluciclovine PET/CT in Recurrent Prostate Cancer
NCT02680041Phase 3Completed
- Sponsor
- Blue Earth Diagnostics
- Start
- Jun 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluciclovine f 18 in prostate cancer (PCa), sponsored by Blue Earth Diagnostics. Primary endpoint: The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease. Started Jun 2016; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02680041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680041.